Fujian Cosunter Pharmaceutical Co Ltd

Fujian Cosunter Pharmaceutical Co Ltd exhibits a weak capital structure and liquidity position, with a debt-to-equity ratio of 1.64 and a current ratio of 1.08, indicating limited short-term liquidity. The company's free cash flow is negative at -223.6 million CNY, and operating cash flow is also negative at -35.1 million CNY, suggesting ongoing cash flow challenges. The negative net cash position after subtracting total debt further highlights the company's liquidity risk. Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of 217.8 million CNY and an operating loss of 228.4 million CNY, with a return on equity of -78.5% and a return on assets of -15.56%. These figures indicate a significant deviation from the typical performance of firms in the pharmaceutical industry, where positive returns and stable margins are expected. The company's revenue is concentrated in a single geographic market, with no disclosed international operations. This lack of diversification increases exposure to local economic and regulatory risks. No segment-specific revenue breakdown is available, but the absence of disclosed international operations suggests a high degree of domestic concentration. The company's growth trajectory is negative, with a net loss in the most recent fiscal year. No forward-looking revenue guidance is provided, and the absence of disclosed capital expenditures or R&D investments suggests limited near-term growth initiatives. The company's operating income and net income are both negative, indicating a lack of profitability and potential operational inefficiencies. The company faces significant financial and operational risks, including a high debt load and negative cash flows. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. No recent dilutive events are disclosed, and the company has not issued new shares in the latest reporting period. No recent events, such as earnings calls, regulatory filings, or press releases, are disclosed in the available data. The absence of recent disclosures may indicate limited transparency or a lack of material developments in the company's operations.